175250 — Icure Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- KR₩71bn
- KR₩140bn
- KR₩57bn
- 19
- 31
- 40
- 15
Annual income statement for Icure Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 60,922 | 90,144 | 64,283 | 59,367 | 56,806 |
| Cost of Revenue | |||||
| Gross Profit | 18,210 | 18,097 | -4,659 | -5,580 | 1,298 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 67,301 | 100,648 | 96,692 | 87,511 | 81,702 |
| Operating Profit | -6,379 | -10,504 | -32,409 | -28,144 | -24,895 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8,513 | -11,498 | -38,835 | -43,090 | -32,525 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8,654 | -12,150 | -38,384 | -42,549 | -32,299 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -8,751 | -12,614 | -38,167 | -41,766 | -31,420 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -8,751 | -12,614 | -38,167 | -41,766 | -31,420 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -412 | -664 | -1,423 | -1,753 | -799 |
| Dividends per Share |